News Releases

Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.

Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026

Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio

Emiltatug Ledadotin (Emi-Le) Granted Breakthrough Therapy Designation by the U.S. FDA for Adenoid Cystic Carcinoma (ACC)

Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)

Servier completes the acquisition of Day One Biopharmaceuticals

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio